Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Exscientia Announces Investment of up to $525M
Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities
$225 million Series D round closed with access up to an additional $300 million at Exscientia s discretion
Financing led by SoftBank Vision Fund 2
Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2
i led the Series D and was joined by previous round lead investors, Novo Holdings and funds managed by Blackrock. Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company s discretion.
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer s disease
Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer s disease medicines that alleviate the burden of devastating disease
Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer s disease (AD).
AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia.
1,2 Symptoms of this progressive disease are debilitating, distressing for both those with the disease and their loved ones and there is currently no cure.